Dr. Reddy's Laboratories acquires injectable product portfolio from Eton Pharma
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
This is the first Agilent lab to receive the My Green Lab Certification and plans are under way to certify additional labs.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
QIAGEN has started its cloud transformation journey with the firm belief that cloud computing can be a key enabler of future business growth
The three-year collaboration will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the next generation of molecular machine learning
Gilman will be responsible for all business development and portfolio strategy efforts globally.
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
The Ayushman Bharat Digital Mission (ABDM) aims to replicate this success in healthcare delivery by building an equitable, accessible and inclusive ecosystem
Subscribe To Our Newsletter & Stay Updated